Streetbeat News

Regulatory

NVDA

NVIDIA has stated that the additional licensing requirements for exports to China and other countries, imposed by the Interim Final Rule, will not have a significant impact on their financial results due to the strong demand for their products worldwide. The rule affects the export of certain integrated circuits, including the A100, A800, H100, H800, L40, L40S, and RTX 4090.

Portfolio Pulse from Benzinga Newsdesk

October 17, 2023 | 9:42 pm

TSLA

Tesla Inc (NASDAQ:TSLA) has launched the Cyberquad, a small electric toy version of the Cybertruck, in Europe. The vehicle, recommended for children aged 8 to 12, sold out in the U.S. in under 24 hours but was later recalled and banned in October 2022. The Cyberquad is now available in the Tesla online store for Europe at a price of 1,990 Euros, or around $2,105 in U.S. dollars.

Portfolio Pulse from Chris Katje

October 17, 2023 | 9:33 pm

SPY

Bloomberg reporter Erik Wasson tweeted that there will be no more House votes today, with further votes scheduled for 11am tomorrow.

Portfolio Pulse from Charles Gross

October 17, 2023 | 9:16 pm

FFIC

Faraday Future Intelligent Electric Inc. has regained compliance with Nasdaq Listing Rule 5605(b)(1) following the resignation of board member Ke Sun. The company was previously non-compliant due to not having a majority of independent directors. The board has now determined that Ms. Li Han is independent, and reduced the board size from seven to six members, resolving the issue.

Portfolio Pulse from Charles Gross

October 17, 2023 | 8:59 pm

DMK

DMK Pharmaceuticals received a notice from Nasdaq on October 11, stating that the company's common stock is subject to delisting unless the company requests a hearing before a panel in a timely manner.

Portfolio Pulse from Benzinga Newsdesk

October 17, 2023 | 8:41 pm

MIRM

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) announced that the FDA has extended the review of the sNDA for LIVMARLI® (maralixibat) oral solution for the treatment of cholestatic pruritus in patients with PFIC. The new PDUFA date is March 13, 2024. The FDA extended the date to allow time for a full review of a submission provided in response to an FDA information request. No additional data or studies have been requested.

Portfolio Pulse from Benzinga Newsdesk

October 17, 2023 | 8:37 pm

AMAM

Ambrx Biopharma has filed for up to $300 million of securities offerings, according to a recent filing.

Portfolio Pulse from Benzinga Newsdesk

October 17, 2023 | 8:31 pm

ORIC

ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) will present two poster presentations at the European Society of Medical Oncology (ESMO) Congress 2023. The presentations will highlight the initial Phase 1b clinical data for ORIC-114 in EGFR/HER2 exon 20 mutated cancers and new preclinical data for ORIC-114 demonstrating activity against additional atypical mutations in EGFR. A conference call and webcast will be hosted by ORIC on October 21, 2023.

Portfolio Pulse from Benzinga Newsdesk

October 17, 2023 | 8:31 pm

EIS

SPY

VGK

U.S. President Biden is considering a $100 billion funding request that includes aid for Israel and Ukraine, according to a report by Bloomberg cited by Reuters.

Portfolio Pulse from Benzinga Newsdesk

October 17, 2023 | 8:27 pm

BLTE

Belite Bio has announced its submission to the National Medical Products Administration (NMPA) for the Phase 3 clinical trial of Tinlarebant in China. The drug is aimed at treating gouty arthritis (GA).

Portfolio Pulse from Benzinga Newsdesk

October 17, 2023 | 8:24 pm